New hope for advanced lung cancer patients with no other options
NCT ID NCT07535359
First seen May 05, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This program offers access to an experimental drug called I-DXd for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments. It is for patients who have no suitable treatment options and cannot join a clinical trial. The goal is to provide potential benefit while gathering more information about the drug's effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Central Care Cancer Center
AVAILABLESalina, Kansas, 67401, United States
Contact
-
Duke Cancer Institute
AVAILABLEDurham, North Carolina, 27710, United States
Contact
-
University of Texas Southwestern Medical
AVAILABLEDallas, Texas, 75390, United States
Contact
Conditions
Explore the condition pages connected to this study.